Protein Engineering Design and Selection · 2008 · 14 citations · 49 references
Life SciencesImmunologyOncologyCancer ImmunologyCellular ImmunologyTumor ImmunologyCancer ImmunotherapyNatural Killer Cell BiologyNatural Killer Cell TherapyProtein TargetingTumor BiologyCancer Cell LysisCell LysisHost Cell LysisInhibitory Killer Cell Immunoglobulin-like ReceptorsNatural Killer Cell Inhibitory SignalingNk Cell Activating LigandsNk Cell Engineering
Natural killer (NK) cells are at the crossroad between innate and adaptive immunity and play a major role in cancer immunosurveillance. NK cell stimulation depends on a balance between inhibitory and activating receptors, such as the stimulatory lectin-like receptor NKG2D. To redirect NK cells against tumor cells, we designed bifunctional proteins able to specifically bind tumor cells and to induce their lysis by NK cells, after NKG2D engagement. To this aim, we used the 'knob into hole' heterodimerization strategy, in which 'knob' and 'hole' variants were generated by directed mutagenesis within the CH3 domain of human IgG1 Fc fragments fused to an anti-CEA or anti-HER2 scFv or to the H60 murine ligand of NKG2D, respectively. We demonstrated the capacity of the bifunctional proteins produced to specifically coat tumor cells surface with H60 ligand. Most importantly, we demonstrated that these bifunctional proteins were able to induce an NKG2D-dependent and antibody-specific tumor cell lysis by murine NK cells. Overall, the results show the possibility to redirect NK cytotoxicity to tumor cells by a new format of recombinant bispecific antibody, opening the way of potential NK cell-based cancer immunotherapies by specific activation of the NKG2D receptor at the tumor site.
49
The journal of clinical investigation
Journal of the American Dietetic Association · 1994 · 1.2K citations · Full text
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Andreas Diefenbach, Eric R. Jensen, A. M. Jamieson et al. · Nature · 2001 · 1.1K citations · Full text
Life Sciences, Immunology, Oncology +14